BEAUTY HEALTH CO/THE (SKIN) Stock Fundamental Analysis

NASDAQ:SKIN • US88331L1089

1.08 USD
+0.04 (+3.85%)
At close: Mar 2, 2026
1.08 USD
0 (0%)
After Hours: 3/2/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SKIN. SKIN was compared to 37 industry peers in the Personal Care Products industry. The financial health of SKIN is average, but there are quite some concerns on its profitability. SKIN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • SKIN had negative earnings in the past year.
  • In the past year SKIN had a positive cash flow from operations.
  • In the past 5 years SKIN reported 4 times negative net income.
  • In multiple years SKIN reported negative operating cash flow during the last 5 years.
SKIN Yearly Net Income VS EBIT VS OCF VS FCFSKIN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

  • SKIN's Return On Assets of -2.33% is in line compared to the rest of the industry. SKIN outperforms 43.24% of its industry peers.
  • With a Return On Equity value of -17.89%, SKIN perfoms like the industry average, outperforming 40.54% of the companies in the same industry.
Industry RankSector Rank
ROA -2.33%
ROE -17.89%
ROIC N/A
ROA(3y)-3.53%
ROA(5y)-10.89%
ROE(3y)-66.06%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SKIN Yearly ROA, ROE, ROICSKIN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

  • Looking at the Gross Margin, with a value of 66.57%, SKIN is in line with its industry, outperforming 51.35% of the companies in the same industry.
  • In the last couple of years the Gross Margin of SKIN has declined.
  • SKIN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 66.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.45%
GM growth 5YN/A
SKIN Yearly Profit, Operating, Gross MarginsSKIN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • SKIN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • SKIN has more shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, SKIN has a worse debt to assets ratio.
SKIN Yearly Shares OutstandingSKIN Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 50M 100M 150M
SKIN Yearly Total Debt VS Total AssetsSKIN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • Based on the Altman-Z score of -0.20, we must say that SKIN is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -0.20, SKIN is doing worse than 72.97% of the companies in the same industry.
  • SKIN has a debt to FCF ratio of 10.65. This is a negative value and a sign of low solvency as SKIN would need 10.65 years to pay back of all of its debts.
  • SKIN has a Debt to FCF ratio of 10.65. This is comparable to the rest of the industry: SKIN outperforms 51.35% of its industry peers.
  • A Debt/Equity ratio of 5.53 is on the high side and indicates that SKIN has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 5.53, SKIN is doing worse than 78.38% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 5.53
Debt/FCF 10.65
Altman-Z -0.2
ROIC/WACCN/A
WACC5.99%
SKIN Yearly LT Debt VS Equity VS FCFSKIN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • SKIN has a Current Ratio of 4.98. This indicates that SKIN is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of SKIN (4.98) is better than 89.19% of its industry peers.
  • SKIN has a Quick Ratio of 4.07. This indicates that SKIN is financially healthy and has no problem in meeting its short term obligations.
  • SKIN's Quick ratio of 4.07 is amongst the best of the industry. SKIN outperforms 89.19% of its industry peers.
Industry RankSector Rank
Current Ratio 4.98
Quick Ratio 4.07
SKIN Yearly Current Assets VS Current LiabilitesSKIN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The earnings per share for SKIN have decreased strongly by -30.18% in the last year.
  • The Revenue for SKIN has decreased by -13.15% in the past year. This is quite bad
  • SKIN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.72% yearly.
EPS 1Y (TTM)-30.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-13.15%
Revenue growth 3Y8.73%
Revenue growth 5YN/A
Sales Q2Q%-10.34%

3.2 Future

  • SKIN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 33.71% yearly.
  • SKIN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.40% yearly.
EPS Next Y63.91%
EPS Next 2Y17.79%
EPS Next 3Y-1.31%
EPS Next 5Y33.71%
Revenue Next Year-9.64%
Revenue Next 2Y-2.86%
Revenue Next 3Y-0.97%
Revenue Next 5Y1.4%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
SKIN Yearly Revenue VS EstimatesSKIN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2032 100M 200M 300M 400M 500M
SKIN Yearly EPS VS EstimatesSKIN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 0 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SKIN. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SKIN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SKIN Price Earnings VS Forward Price EarningsSKIN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

  • SKIN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. SKIN is cheaper than 97.30% of the companies in the same industry.
Industry RankSector Rank
P/FCF 4.04
EV/EBITDA N/A
SKIN Per share dataSKIN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.79%
EPS Next 3Y-1.31%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • SKIN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BEAUTY HEALTH CO/THE

NASDAQ:SKIN (3/2/2026, 8:00:02 PM)

After market: 1.08 0 (0%)

1.08

+0.04 (+3.85%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)11-06
Earnings (Next)03-12
Inst Owners88.15%
Inst Owner Change1.63%
Ins Owners11.44%
Ins Owner Change10.37%
Market Cap137.70M
Revenue(TTM)301.92M
Net Income(TTM)-11.74M
Analysts51.43
Price Target2 (85.19%)
Short Float %14.29%
Short Ratio28.74
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)62.73%
Min EPS beat(2)-30.18%
Max EPS beat(2)155.64%
EPS beat(4)3
Avg EPS beat(4)47.59%
Min EPS beat(4)-30.18%
Max EPS beat(4)155.64%
EPS beat(8)7
Avg EPS beat(8)51.89%
EPS beat(12)10
Avg EPS beat(12)48.9%
EPS beat(16)13
Avg EPS beat(16)418.68%
Revenue beat(2)2
Avg Revenue beat(2)1.95%
Min Revenue beat(2)0.99%
Max Revenue beat(2)2.9%
Revenue beat(4)4
Avg Revenue beat(4)4.15%
Min Revenue beat(4)0.99%
Max Revenue beat(4)6.94%
Revenue beat(8)6
Avg Revenue beat(8)2.34%
Revenue beat(12)7
Avg Revenue beat(12)-0.39%
Revenue beat(16)11
Avg Revenue beat(16)2.61%
PT rev (1m)1.29%
PT rev (3m)1.29%
EPS NQ rev (1m)-14.29%
EPS NQ rev (3m)-11.2%
EPS NY rev (1m)20.84%
EPS NY rev (3m)47.23%
Revenue NQ rev (1m)-0.03%
Revenue NQ rev (3m)-0.57%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.46
P/FCF 4.04
P/OCF 3.55
P/B 2.1
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.22
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)0.27
FCFY24.78%
OCF(TTM)0.3
OCFY28.15%
SpS2.37
BVpS0.51
TBVpS-0.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2.33%
ROE -17.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 66.57%
FCFM 11.3%
ROA(3y)-3.53%
ROA(5y)-10.89%
ROE(3y)-66.06%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.45%
GM growth 5YN/A
F-Score6
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 5.53
Debt/FCF 10.65
Debt/EBITDA N/A
Cap/Depr 20.73%
Cap/Sales 1.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.98
Quick Ratio 4.07
Altman-Z -0.2
F-Score6
WACC5.99%
ROIC/WACCN/A
Cap/Depr(3y)42.98%
Cap/Depr(5y)45.87%
Cap/Sales(3y)3.35%
Cap/Sales(5y)3.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y63.91%
EPS Next 2Y17.79%
EPS Next 3Y-1.31%
EPS Next 5Y33.71%
Revenue 1Y (TTM)-13.15%
Revenue growth 3Y8.73%
Revenue growth 5YN/A
Sales Q2Q%-10.34%
Revenue Next Year-9.64%
Revenue Next 2Y-2.86%
Revenue Next 3Y-0.97%
Revenue Next 5Y1.4%
EBIT growth 1Y16.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year147.59%
EBIT Next 3Y35.69%
EBIT Next 5Y34.66%
FCF growth 1Y335.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y80.03%
OCF growth 3YN/A
OCF growth 5YN/A

BEAUTY HEALTH CO/THE / SKIN FAQ

Can you provide the ChartMill fundamental rating for BEAUTY HEALTH CO/THE?

ChartMill assigns a fundamental rating of 2 / 10 to SKIN.


What is the valuation status of BEAUTY HEALTH CO/THE (SKIN) stock?

ChartMill assigns a valuation rating of 2 / 10 to BEAUTY HEALTH CO/THE (SKIN). This can be considered as Overvalued.


Can you provide the profitability details for BEAUTY HEALTH CO/THE?

BEAUTY HEALTH CO/THE (SKIN) has a profitability rating of 1 / 10.


Can you provide the financial health for SKIN stock?

The financial health rating of BEAUTY HEALTH CO/THE (SKIN) is 4 / 10.


What is the earnings growth outlook for BEAUTY HEALTH CO/THE?

The Earnings per Share (EPS) of BEAUTY HEALTH CO/THE (SKIN) is expected to grow by 63.91% in the next year.